-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This type of cancer is effectively treated in rodent models, leading to new treatments for bone metastases, according to a study by scientists at Rice University and Baylor College of Medicine.
The open-access study, which will appear on the cover of the American Chemical Society's ACS Central Science journal, advances a technique pioneered by Rice University chemist Han Xiao and his Baylor co-author, biologist Xiang Zhang
Through extensive testing, they found that engineering a "bone-homing" peptide and attaching it to a common breast cancer drug, the antibody trastuzumab, could effectively target and attack bone tumors
The researchers reported their surprise that injecting more of the drug compound didn't make it better
"The negative charge of the peptide has an affinity for the positively charged bone cancer niche," said Xiao, whose lab created a library of modified antibodies for testing
As many as 40 percent of breast cancer survivors eventually experience metastases to distant organs, most commonly to bone
Studies have shown that peptide-enhancing antibodies can also prevent secondary metastases from bone to other organs
The researchers hope to find collaborators to move the strategy to human trials
Zeru Tian, Chenfei Yu, Weijie Zhang, Kuan-Lin Wu, Chenhang Wang, Ruchi Gupta, Zhan Xu, Ling Wu, Yuda Chen, Xiang H.
